The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs. (SCOOP)
Study of Satellite Cells in COPD-associated sarcOPenia (Satellite Cells in COPD Sarcopenia) : Exploratory Cohort Study for Translational Research
The aim of the study is to decipher the alterations in signalling pathways of skeletal muscle stem cells (satellite cells (SCs)) in individuals with COPD, as well as to examine the effect of exercise training on SCs. To this end, the team will perform an exhaustive evaluation of lung and muscle function, including exercise capacity, as well as muscle biopsies, before and after a 2-months rehabilitation program. This study should provide new therapeutic avenues for COPD-associated sarcopenia.
調査の概要
詳細な説明
Chronic obstructive pulmonary disease (COPD) is now to be considered as a multimorbid disease, originating from a combination of several risk factors (respiratory events in childhood, exposure to inhaled particles, physical inactivity, etc.), and simultaneously affecting several organs. This multi-organ impairment is likely to arise from common biological processes such as systemic inflammation or repair failure. Studying these processes in an organ that is easily accessible to biopsy, such as skeletal muscle, can help in the overall management of COPD. Skeletal muscle wasting (or sarcopenia: loss of muscle mass and force) is also a major comorbidity in COPD, both frequent and associated to increased mortality. Muscle stem cells (satellite cells) are responsible for repairing skeletal muscle tissue after injury, notably after micro-lesions induced by exercise. However, they have been scarcely studied in COPD. In the present project, the team proposes to study repair abnormalities in skeletal muscle tissue by comparing the signalling pathways activated in satellite cells of patients with COPD, before and after a respiratory rehabilitation programme (20 sessions over 8 to 12 weeks). The team will carry out an exhaustive respiratory and muscular assessment at inclusion and at the end of the 20 sessions, evaluating in particular respiratory function and exercise capacity (Pulmonary Function Tests, cardio-pulmonary exercise testing with VO2max measurement, 6-minute walking test, handgrip test) as well as a quadricipital muscle biopsy with the modified Bergström's technique. Muscle biopsies will be used to culture satellite cells and assess their regenerative capacity in vitro, as well as to analyse dysregulated signalling pathways at the transcriptomic level with single-cell RNAsequencing. The results should help to identify new therapeutic avenues for the comprehensive management of multimorbid COPD.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Pauline HENROT, MD
- 電話番号：+33(0)5 57 65 65 13
- メール：pauline.henrot@chu-bordeaux.fr
研究場所
-
-
-
Créteil、フランス、94000
- Hôpital Henri-Mondor
-
コンタクト：
- Laurent BOYER, MD, PhD
- 電話番号：+33(0)1 49 81 26 81
- メール：laurent.boyer@aphp.fr
-
Paris、フランス、75013
- Hôpital Pitié-Salpêtrière
-
コンタクト：
- Romy RATSIHORIMANANA, MD
- 電話番号：+33(0)1 42 16 77 99
- メール：romy.ratsihorimanana@aphp.fr
-
Pessac、フランス、33400
- CHU de Bordeaux
-
コンタクト：
- Pauline HENROT, MD
- 電話番号：+33(0)5 57 65 65 13
- メール：pauline.henrot@chu-bordeaux.fr
-
主任研究者：
- Pauline HENROT, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adult male or female (age 18 years or older);
- Having a diagnosis of COPD according to the GOLD (Global Initiative for Lung Disease) 2024 criteria, i.e. a non-reversible bronchial obstruction in spirometry with a post-bronchodilator Tiffeneau coefficient < 70%;
- Less than or equal to 75 years of age;
- Must benefit from exercise retraining sessions or respiratory rehabilitation as part of the management of COPD;
- Person affiliated to or beneficiary of a social security scheme (excluding State Medical Aid (AME));
- Free, informed and written consent signed by the participant or by a third party (in the event of the participant's physical disability) and the investigator (no later than the day of inclusion and before any review required by the research).
Exclusion Criteria:
- Moderate or severe acute exacerbation of COPD, or acute intercurrent condition (e.g., infection) that has been ongoing or resolved for less than 4 weeks;
- Systemic corticosteroid therapy in progress or stopped for less than 4 weeks;
- Contraindication to respiratory rehabilitation: tight aortic stenosis, unstable heart failure, active thromboembolic disease, ventricular aneurysm, uncontrolled arrhythmias;
- Contraindication to muscle biopsy: acquired or innate haemostasis disorders, anticoagulant treatment or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
- Presence of a concomitant muscle pathology, innate (e.g., genetic myopathy) or acquired (e.g., myositis, progressive cancer);
- Pregnant or breastfeeding woman;
- Patient under guardianship or curatorship;
- Refusal to participate in the study.
Exclusion criteria:
- Hemostasis disorders.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Men or women (adults) with a diagnosis of COPD according to GOLD criteria
|
Patients will undergo an exhaustive respiratory and muscular check-up (including quadridipital muscle biopsies) at inclusion and at the end of the respiratory rehabilitation program (a minimum of 20 sessions at a rate of 2 to 3 sessions per week for 8 to 12 weeks). |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in single-cell gene expression profile of muscle satellite cells after pulmonary rehabilitation
時間枠：Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)
|
Intra-individual comparison of messenger RNA (mRNA) expression in muscle satellite cells isolated from quadriceps muscle biopsies collected before and after the pulmonary rehabilitation programme. Satellite cells will be isolated and analysed using single-cell and single-nucleus RNA sequencing. The outcome is the change in the gene-expression profile, including differentially expressed genes and associated molecular signalling pathways, between baseline and the end of rehabilitation. |
Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)
|
協力者と研究者
捜査官
- 主任研究者：Pauline HENROT、University Hospital, Bordeaux
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CHUBX 2026/005
- 2026-A00609-42 (その他の識別子：French National Agency for Safety of Medicines and Health Products)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data is available from Dr HENROT . An email can be sent to her so that she can contact the data manager and owner, the Bordeaux University Hospital. The data can be made available after contractual agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。